Key result
Temporary paracorporeal LVAD bridges fulminant Parvovirus B19 myocarditis to myocardial recovery at ~9 days.
Why the study?
There is no consensus on the surgical strategy for fulminant myocarditis caused by Parvovirus B19, particularly regarding the use of single versus biventricular mechanical support.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
May support temporary LVAD bridging to recovery in select Parvovirus B19 myocarditis; leaves open generalizability pending prospective data.
We present the case of a 18-year-old female with fulminant lymphocytic myocarditis caused by Parvovirus B19 (PVB19), successfully treated using temporary LVAD. In the literature there is no consensus on the surgical strategy. While some surgeons prefer to use a single device supporting only the LV, others prefer to start immediately with a biventricular supporting. At pre-procedural ultrasound evaluation, her anatomical features were not suitable for a percutaneous device such as the Impella. Thus, a temporary paracorporeal continuous flow LVAD was inserted. The heart recovery allowed LVAD removal 9 days after the implant.
No takes yet. Share an insight, caveat, or question.
Pesce et al. (2021) conducted a case report in Fulminant lymphocytic myocarditis caused by Parvovirus B19 (n=1). Temporary paracorporeal continuous flow LVAD was evaluated on Survival and left ventricular recovery. A temporary paracorporeal continuous flow LVAD successfully treated an 18-year-old woman with Parvovirus B19-related fulminant lymphocytic myocarditis, allowing for heart recovery and device removal after 9 days.
Synapse has enriched 10 related papers. Consider them for comparative context: